Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

Noens, Lucien; van Lierde, Marie-Anne; De Bock, R.; Verhoef, Gregor; Zachée, Pierre; Berneman, Zwi; Martiat, Philippe; Mineur, Philippe; Van Eygen, Koen; MacDonald, Karen; De Geest, Sabina; Albrecht, Tara; Abraham, Ivo

doi:10.1182/blood-2008-12-196543

Public

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

Published in Blood • Apr 7, 2009

Authors:

Lucien Noens

Marie-Anne van Lierde

R. De Bock

Abstract

Imatinib mesylate (imatinib) has been shown to be highly efficacious in the treatment of chronic myeloid leukemia (CML). Continuous and adequate dosing is essential for optimal outcomes and with imatinib treatment possibly being lifelong, patient adherence is critical. The ADAGIO (Adherence Assessme...

Subject

Imatinib

Myeloid leukemia

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!